Center for Thoracic Disease, Heart and Lung Institute, St Joseph's Hospital and Medical Center, Phoenix, AZ 85013, USA.
J Thorac Cardiovasc Surg. 2011 Feb;141(2):523-30. doi: 10.1016/j.jtcvs.2010.10.006. Epub 2010 Dec 15.
Obliterative bronchiolitis is the predominant histopathologic finding in patients with chronic rejection after lung transplant. This fibroproliferative transformation within small airways of lung allograft is poorly understood; however, studies suggest epithelial-mesenchymal transition plays a role. Transplant immunosuppressive therapy has been shown to cause epithelial-mesenchymal transition in renal tubular epithelial cells, with subsequent fibrosis. This study explored whether immunosuppressive therapy contributes to epithelial-mesenchymal transition in airway epithelial cells.
Bronchial epithelial cell line RL-65 was treated 3 to 5 days with several immunosuppressive agents, including cyclosporine (INN ciclosporin), tacrolimus, azathioprine, mycophenolic acid, sirolimus, prednisone, and transforming growth factor β1 as control. We then analyzed cells for presence of mesenchymal morphology and protein markers.
Treatment with cyclosporine, azathioprine, mycophenolate, and sirolimus resulted in elongated and irregular cell shape, and all but azathioprine showed loss of cell-cell adhesions relative to vehicle-treated cells. Expressions of extracellular matrix proteins, fibronectin and collagen, along with mesenchymal marker, vimentin, were significantly upregulated. Immunofluorescence showed loss of E-cadherin at cell membranes and cytoskeletal rearrangements typical of epithelial-mesenchymal transition. These immunosuppressive agents also increased transforming growth factor produced by cells; however, tacrolimus- and prednisone-treated cells maintained epithelial morphology, baseline levels of matrix protein expression, and transforming growth factor production levels.
Overall, we found that certain immunosuppressive agents may contribute to partial epithelial-mesenchymal transition in bronchial epithelial cells, specifically increasing production of excessive extracellular matrix proteins. This may provide novel insights into the pathogenesis of obliterative bronchiolitis after lung transplant.
闭塞性细支气管炎是肺移植后慢性排斥反应患者的主要组织病理学表现。肺移植后,这种小气道的纤维增生性转化尚不清楚;然而,研究表明上皮-间充质转化起作用。移植免疫抑制疗法已被证明可导致肾近端小管上皮细胞发生上皮-间充质转化,随后发生纤维化。本研究探讨了免疫抑制疗法是否导致气道上皮细胞发生上皮-间充质转化。
用几种免疫抑制剂处理支气管上皮细胞系 RL-65 3 至 5 天,包括环孢素(INN 环孢素)、他克莫司、硫唑嘌呤、霉酚酸、西罗莫司、泼尼松和转化生长因子β1 作为对照。然后分析细胞是否存在间充质形态和蛋白标志物。
环孢素、硫唑嘌呤、霉酚酸和西罗莫司处理导致细胞形状拉长和不规则,除硫唑嘌呤外,所有药物处理的细胞与载体处理的细胞相比,细胞-细胞黏附均丧失。细胞外基质蛋白纤维连接蛋白和胶原蛋白以及间充质标志物波形蛋白的表达明显上调。免疫荧光显示细胞表面 E-钙黏蛋白丢失和细胞骨架重排,这些均为上皮-间充质转化的典型特征。这些免疫抑制剂还增加了细胞产生的转化生长因子;然而,他克莫司和泼尼松处理的细胞保持上皮形态、基质蛋白表达和转化生长因子产生水平的基线。
总之,我们发现某些免疫抑制剂可能导致支气管上皮细胞发生部分上皮-间充质转化,特别是增加细胞外基质蛋白的过度产生。这可能为肺移植后闭塞性细支气管炎的发病机制提供新的见解。